Dr. Seth M. Pollack
Claim this profileNorthwestern University
Studies Soft Tissue Sarcoma
Studies Uterine Leiomyosarcoma
19 reported clinical trials
29 drugs studied
Area of expertise
1Soft Tissue Sarcoma
Stage IV
Stage III
FGFR positive
2Uterine Leiomyosarcoma
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Seth M. Pollack is currently running
ADI-PEG 20 + Chemotherapy
for Leiomyosarcoma
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Recruiting1 award Phase 310 criteria
Zanzalintinib
for Leiomyosarcoma
This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Leiomyosarcomas are a type sarcoma that can occur in any location in the body, such as the uterus or in the abdomen. Current standard treatment for leiomyosarcoma only shows a progression-free survival of 4-6 months. XL092, a tyrosine kinase inhibitor, interferes with cell communication and growth and may prevent tumor growth. Giving XL092 may kill more tumor cells in patients with metastatic or unresectable leiomyosarcoma.
Recruiting1 award Phase 28 criteria
More about Seth M. Pollack
Clinical Trial Related2 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Seth M. Pollack has experience with
- Cabozantinib
- Placebo
- Doxorubicin
- Temozolomide
- Nivolumab
- Dacarbazine
Breakdown of trials Seth M. Pollack has run
Soft Tissue Sarcoma
Uterine Leiomyosarcoma
Cancer
Leiomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Seth M. Pollack specialize in?
Seth M. Pollack focuses on Soft Tissue Sarcoma and Uterine Leiomyosarcoma. In particular, much of their work with Soft Tissue Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Seth M. Pollack currently recruiting for clinical trials?
Yes, Seth M. Pollack is currently recruiting for 4 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Seth M. Pollack has studied deeply?
Yes, Seth M. Pollack has studied treatments such as Cabozantinib, Placebo, Doxorubicin.
What is the best way to schedule an appointment with Seth M. Pollack?
Apply for one of the trials that Seth M. Pollack is conducting.
What is the office address of Seth M. Pollack?
The office of Seth M. Pollack is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.